Empirical_JJ Bayesian_JJ data_NNS mining_NN for_IN discovering_VBG patterns_NNS in_IN post-marketing_JJ drug_NN safety_NN
Because_IN of_IN practical_JJ limits_NNS in_IN characterizing_VBG the_DT safety_NN profiles_NNS of_IN therapeutic_JJ products_NNS prior_RB to_TO marketing_NN ,_, manufacturers_NNS and_CC regulatory_JJ agencies_NNS perform_VBP post-marketing_JJ surveillance_NN based_VBN on_IN the_DT collection_NN of_IN adverse_JJ reaction_NN reports_NNS -LRB-_-LRB- ``_`` pharmacovigilance_NN ''_'' -RRB-_-RRB- ._.
The_DT resulting_VBG databases_NNS ,_, while_IN rich_JJ in_IN real-world_JJ information_NN ,_, are_VBP notoriously_RB difficult_JJ to_TO analyze_VB using_VBG traditional_JJ techniques_NNS ._.
Each_DT report_NN may_MD involve_VB multiple_JJ medicines_NNS ,_, symptoms_NNS ,_, and_CC demographic_JJ factors_NNS ,_, and_CC there_EX is_VBZ no_DT easily_RB linked_VBN information_NN on_IN drug_NN exposure_NN in_IN the_DT reporting_NN population_NN ._.
KDD_NN techniques_NNS ,_, such_JJ as_IN association_NN finding_NN ,_, are_VBP well-matched_JJ to_TO the_DT problem_NN ,_, but_CC are_VBP difficult_JJ for_IN medical_JJ staff_NN to_TO apply_VB and_CC interpret_VB ._.
To_TO deploy_VB KDD_NNP effectively_RB for_IN pharmacovigilance_NN ,_, Lincoln_NNP Technologies_NNP and_CC GlaxoSmithKline_NNP collaborated_VBD to_TO create_VB a_DT webbased_JJ safety_NN data_NNS mining_NN web_NN environment_NN ._.
The_DT analytical_JJ core_NN is_VBZ a_DT high-performance_JJ implementation_NN of_IN the_DT MGPS_NNP -LRB-_-LRB- Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -RRB-_-RRB- algorithm_NN described_VBN previously_RB by_IN DuMouchel_NNP and_CC Pregibon_NNP ,_, with_IN several_JJ significant_JJ extensions_NNS and_CC enhancements_NNS ._.
The_DT environment_NN offers_VBZ an_DT interface_NN for_IN specifying_VBG data_NNS mining_NN runs_VBZ ,_, a_DT batch_NN execution_NN facility_NN ,_, tabular_JJ and_CC graphical_JJ methods_NNS for_IN exploring_VBG associations_NNS ,_, and_CC drilldown_NN to_TO case_NN details_NNS ._.
Substantial_JJ work_NN was_VBD involved_VBN in_IN preparing_VBG the_DT raw_JJ adverse_JJ event_NN data_NNS for_IN mining_NN ,_, including_VBG harmonization_NN of_IN drug_NN names_NNS and_CC removal_NN of_IN duplicate_VB reports_NNS ._.
The_DT environment_NN can_MD be_VB used_VBN to_TO explore_VB both_CC drug-event_JJ and_CC multi-way_JJ associations_NNS -LRB-_-LRB- interactions_NNS ,_, syndromes_NNS -RRB-_-RRB- ._.
It_PRP has_VBZ been_VBN used_VBN to_TO study_VB age\/gender_JJ effects_NNS ,_, to_TO predict_VB the_DT safety_NN profiles_NNS of_IN proposed_VBN combination_NN drugs_NNS ,_, and_CC to_TO separate_JJ contributions_NNS of_IN individual_JJ drugs_NNS to_TO safety_NN problems_NNS in_IN polytherapy_JJ situations_NNS ._.
oth_NN financial_JJ and_CC social_JJ reasons_NNS ._.
At_IN present_NN ,_, the_DT early_JJ detection_NN of_IN unexpected_JJ adverse_JJ drug_NN reactions_NNS relies_VBZ on_IN a_DT national_JJ spontaneous_JJ reporting_NN system_NN and_CC collated_VBN statistics_NNS from_IN overseas_JJ agencies_NNS =_JJ -_: =[_NN 1_CD ,_, 2_CD -RRB-_-RRB- -_: =_SYM -_: ._.
â‹†_VB The_DT authors_NNS acknowledge_VBP the_DT Commonwealth_NNP Department_NNP of_IN Health_NNP and_CC Ageing_NNP ,_, and_CC the_DT Queensland_NNP Department_NNP of_IN Health_NNP for_IN providing_VBG data_NNS and_CC support_NN for_IN this_DT research_NN ._.
sHowever_NNP ,_, the_DT recent_JJ availability_NN
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
estimation_NN of_IN the_DT parameters_NNS of_IN the_DT prior_JJ distribution_NN in_IN the_DT empirical_JJ Bayes_NNP model_NN ,_, a_DT summary_NN of_IN the_DT table_NN of_IN counts_NNS and_CC baseline_NN values_NNS ,_, computed_VBN using_VBG the_DT data_NNS squashing_VBG methods_NNS of_IN DuMouchel_NNP et_FW al_FW =_JJ -_: =[_NN 8_CD -RRB-_-RRB- -_: =_JJ -_: is_VBZ substituted_VBN for_IN the_DT much_RB larger_JJR baseline_NN values_NNS file_VBP ._.
5_CD ._.
USER_NNP INTERFACE_NNP &_CC CAPABILITIES_NNP The_NNP WebVDME_NNP user_NN interface_NN is_VBZ organized_VBN around_IN a_DT set_NN of_IN ``_`` tabs_NNS ''_'' and_CC links_NNS that_WDT lead_VBP to_TO major_JJ components_NNS of_IN the_DT
e_LS ``_`` a_DT priori_FW ''_'' method_NN to_TO prune_VB counting_NN of_IN higher-order_JJ associations_NNS when_WRB the_DT counts_NNS for_IN their_PRP$ component_NN lower-order_NN associations_NNS imply_VBP that_IN the_DT higher-order_JJ count_NN can_MD not_RB meet_VB a_DT minimum_JJ count_NN threshold_NN =_JJ -_: =[_NN 7_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Counting_VBG is_VBZ implemented_VBN using_VBG a_DT hash_JJ table_NN to_TO store_VB the_DT count_NN data_NNS ,_, with_IN an_DT ability_NN to_TO write_VB out_RP and_CC merge_VB partial_JJ results_NNS when_WRB working_VBG with_IN very_RB large_JJ problems_NNS that_WDT would_MD exceed_VB available_JJ physical_NN
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
adverse_JJ reactions_NNS -LRB-_-LRB- 1,2,3,4_CD -RRB-_-RRB- ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- =_JJ -_: =[_NN 5_CD -RRB-_-RRB- -_: =_JJ -_: and_CC at_IN the_DT Uppsala_NNP Monitoring_NN Centre_NNP where_WRB Edwards_NNP ,_, Lindquist_NNP ,_, Bate_NNP and_CC others_NNS have_VBP pursued_VBN the_DT use_NN of_IN techniques_NNS based_VBN on_IN Bayesian_JJ neural_JJ networks_NNS -LRB-_-LRB- 6_CD -RRB-_-RRB- ._.
GlaxoSmithKline_NN -LRB-_-LRB- ``_`` GSK_NNP ''_'' -RRB-_-RRB- and_CC Lincoln_NNP Technologie_NNP
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Monitoring_NN Centre_NNP where_WRB Edwards_NNP ,_, Lindquist_NNP ,_, Bate_NNP and_CC others_NNS have_VBP pursued_VBN the_DT use_NN of_IN techniques_NNS based_VBN on_IN Bayesian_JJ neural_JJ networks_NNS =_JJ -_: =[_NN 6_CD -RRB-_-RRB- -_: =_SYM -_: ._.
GlaxoSmithKline_NN -LRB-_-LRB- ``_`` GSK_NNP ''_'' -RRB-_-RRB- and_CC Lincoln_NNP Technologies_NNP -LRB-_-LRB- ``_`` Lincoln_NNP ''_'' -RRB-_-RRB- began_VBD a_DT collaboration_NN in_IN 2001_CD to_TO apply_VB safety_NN data_NNS mining_NN techniques_NNS both_DT to_TO provide_VB direct_JJ leverage_NN in_IN addressing_VBG GSK_NNP 's_POS core_NN business_NN pr_NN
hrinker_NN -LRB-_-LRB- ``_`` GPS_NNP ''_'' -RRB-_-RRB- and_CC Multi-Item_NNP Gamma_NNP Poisson_NNP Shrinker_NNP -LRB-_-LRB- ``_`` MGPS_NNP ''_'' -RRB-_-RRB- techniques_NNS to_TO FDA_NNP 's_POS combined_JJ SRS_NN and_CC AERS_NN databases_NNS and_CC to_TO validate_VB results_NNS retrospectively_RB against_IN known_JJ drug-induced_JJ adverse_JJ reactions_NNS =_JJ -_: =[_NN 1,2,3,4_CD -RRB-_-RRB- -_: =_SYM -_: ._.
Independent_JJ ,_, parallel_JJ efforts_NNS have_VBP proceeded_VBN at_IN the_DT UK_NNP Medicines_NNP Control_NNP Agency_NNP -LRB-_-LRB- MCA_NNP -RRB-_-RRB- where_WRB Dr._NNP Stephen_NNP Evans_NNP has_VBZ explored_VBN the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Moni_NNP
